By Apostolos Manthos Lavipharm (LAVI) enters a new valuation class, as the market begins to reassess not only its current financial sizes, but mainly the profitability and cash flows it can display within the next three years. With the share at EUR 1,69 and capitalisation at EUR 285,68 million, [...]